AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Dr. Reddy's Laboratories Reports Q1 Profit of $165 Million, Revenue of $997 Million
ByAinvest
Wednesday, Jul 23, 2025 1:58 pm ET1min read
Dr. Reddy's Laboratories reported a profit of $165 million in its fiscal first quarter, with revenue of $997 million. The company's net income per share was 20 cents.
Dr. Reddy's Laboratories Ltd, a prominent pharmaceutical company, reported a profit of $165 million in its fiscal first quarter, with revenue reaching $997 million. The company's net income per share was 20 cents [1].The stock, trading under the symbol REDY on the NSE, saw a slight increase of 1.80% to close at 1,259.30 INR on July 2, 2025. The company's stock has been trading within a range of 1,245.20 to 1,262.40 INR over the past day, and its 52-week range is between 1,020.00 to 1,421.49 INR [1].
Dr. Reddy's Laboratories operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products, including biologics. The PSAI segment produces active pharmaceutical ingredients and intermediates, and the Others segment focuses on developing therapies in oncology and inflammation [2].
The company's strong earnings were driven by robust sales in its Global Generics and PSAI segments. The Global Generics segment, which includes the company's biologics business, reported significant growth in revenue and profit. The PSAI segment also contributed to the company's strong financial performance, driven by increased demand for its active pharmaceutical ingredients and contract research services [1].
Analysts have been closely monitoring Dr. Reddy's Laboratories, with several recent updates to their ratings. Macquarie downgraded the stock to Neutral due to concerns about gRevlimid, while Morgan Stanley initiated coverage with an Equalweight rating [3].
The company is expected to announce its quarterly financial results on July 23, 2025, which may impact the stock price. Traders are advised to monitor the latest news and analysis to make informed investment decisions [1].
References:
[1] https://www.investing.com/equities/dr-reddys-laboratories
[2] https://www.investing.com/equities/dr-reddys-laboratories
[3] https://www.investing.com/equities/dr-reddys-laboratories
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet